RLYB revenueQ3 2026$0
- Quarter YoY
- -100.0%
- FY YoY
- +34.9%
RLYB revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $858.0K, up 34.9% from fiscal 2024.
Rallybio Corporation (RLYB) financials
For the twelve months ended Sep 30, 2026, Rallybio Corporation reported $26.81M of net income.
- Net income, TTM
- $26.81M
- EPS, diluted, TTM
- $4.61
- Cash
- $90.69M
- P/E
- 3.14
- Market cap
- $84.3M
FY2024FY2025
FY2020FY2025
FY2020FY2024
RLYB revenue and earnings growth
RLYB net incomeQ3 2026-$2.73M
RLYB net income was -$2.73M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $16.02M a year earlier. For the full fiscal 2025 it was -$8.98M, compared with -$57.77M in fiscal 2024.
RLYB EPSQ3 2026-$0.48
RLYB diluted EPS was -$0.48 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $2.84 a year earlier. For the full fiscal 2025 it was -$1.59, compared with -$10.61 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $858.0K | $636.0K | - | - | - | - |
| Research and development | $19.60M | $41.51M | $53.54M | $40.69M | $26.91M | $17.63M |
| Selling, general and admin | $14.32M | $19.63M | $25.39M | $27.20M | $18.74M | $7.67M |
| Operating income | -$33.06M | -$60.50M | -$78.93M | -$67.88M | -$45.65M | -$25.30M |
| Interest expense | - | - | - | $0 | $10.0K | $49.0K |
| Pre-tax income | -$8.98M | -$55.54M | -$72.52M | -$65.58M | -$45.51M | -$24.94M |
| Income tax | $0 | $0 | $0 | $0 | $0 | -$15.0K |
| Net income | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M | -$26.45M |
| EPS, basic | -$1.59 | -$10.61 | -$14.72 | -$16.72 | -$14.72 | -$12.16 |
| EPS, diluted | -$1.59 | -$10.61 | -$14.72 | -$16.72 | -$14.72 | -$12.16 |
| Diluted shares | 5.6M | 5.4M | 5.1M | 4.0M | 3.2M | 2.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $31.37M | $13.90M | $24.49M | $56.96M | $175.33M | $140.23M |
| Short-term investments | $23.36M | $51.61M | $85.44M | $112.04M | $0 | - |
| Current assets | $61.25M | $67.84M | $114.79M | $179.50M | $180.87M | $141.26M |
| Total assets | $62.26M | $68.11M | $115.62M | $180.44M | $182.19M | $141.86M |
| Current liabilities | $4.22M | $6.24M | $9.26M | $10.74M | $6.55M | $5.84M |
| Total liabilities | $4.30M | $6.45M | $9.44M | $11.12M | $6.58M | $5.86M |
| Shareholders' equity | $57.96M | $61.65M | $106.18M | $169.32M | $175.60M | $136.00M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.81M | -$49.28M | -$60.27M | -$57.28M | -$45.53M | -$22.04M |
| Capital expenditures | - | $0 | $12.0K | $54.0K | $333.0K | $137.0K |
| Free cash flow | - | -$49.28M | -$60.28M | -$57.34M | -$45.87M | -$22.18M |
| Investing cash flow | $47.27M | $33.49M | $27.66M | -$112.17M | -$2.33M | -$2.07M |
| Financing cash flow | $16.0K | $5.20M | $143.0K | $51.08M | $82.97M | $144.89M |
| Stock-based compensation | $5.31M | $7.99M | $10.92M | $9.50M | $3.65M | $704.0K |
| Depreciation and amortization | $92.0K | $131.0K | $150.0K | $167.0K | $109.0K | $62.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | 34.9% | - | - | - | - | - |
| Operating margin | -3853.6% | -9511.9% | - | - | - | - |
| Net margin | -1046.4% | -9084.1% | - | - | - | - |
| Free cash flow margin | - | -7748.7% | - | - | - | - |
| Return on equity | -15.5% | -93.7% | -70.2% | -39.4% | -26.8% | -19.4% |
| Return on assets | -14.4% | -84.8% | -64.5% | -36.9% | -25.8% | -18.6% |
| Current ratio | 14.50 | 10.87 | 12.39 | 16.71 | 27.61 | 24.18 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $212.0K | $222.0K | $212.0K | $212.0K | $212.0K | $38.0K | $299.0K | $299.0K | $0 | - |
| Research and development | $584.0K | $758.0K | $2.87M | $3.65M | $4.14M | $6.07M | $5.72M | $7.38M | $8.24M | $12.95M | $12.94M | $15.92M |
| Selling, general and admin | $2.84M | $4.89M | $6.07M | $2.98M | $2.99M | $4.20M | $4.16M | $4.26M | $4.13M | $4.39M | $6.85M | $5.19M |
| Operating income | -$3.42M | -$5.65M | -$8.73M | -$6.41M | -$6.92M | -$10.06M | -$9.67M | -$11.61M | -$12.07M | -$17.04M | -$19.79M | -$21.11M |
| Pre-tax income | -$2.65M | $44.99M | -$8.28M | -$6.73M | $16.02M | -$9.42M | -$8.85M | -$10.61M | -$10.83M | -$15.75M | -$18.34M | -$19.63M |
| Income tax | $80.0K | $1.32M | $0 | $0 | $0 | $0 | $0 | - | - | - | - | - |
| Net income | -$2.73M | $43.66M | -$8.28M | -$5.85M | $16.02M | -$9.70M | -$9.44M | -$11.04M | -$11.47M | -$16.24M | -$19.03M | -$20.24M |
| EPS, basic | -$0.48 | $7.66 | -$1.46 | -$1.01 | $2.84 | -$1.73 | -$1.69 | -$1.81 | -$2.08 | -$2.96 | -$3.76 | -$4.00 |
| EPS, diluted | -$0.48 | $7.53 | -$1.46 | -$0.98 | $2.84 | -$1.76 | -$1.69 | -$1.81 | -$2.08 | -$2.96 | -$3.76 | -$4.00 |
| Diluted shares | 5.7M | 5.8M | 5.7M | - | 5.6M | 5.6M | 5.6M | - | 5.6M | 5.5M | 5.1M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $90.69M | $92.85M | $41.30M | $31.37M | $32.12M | $9.45M | $14.78M | $13.90M | $25.32M | $16.67M | $19.30M | $24.49M |
| Short-term investments | $0 | $0 | $5.50M | $23.36M | $27.20M | $36.30M | $39.72M | $51.61M | $49.82M | $71.94M | $74.87M | $85.44M |
| Current assets | $94.77M | $97.25M | $53.49M | $61.25M | $66.63M | $50.27M | $57.38M | $67.84M | $78.23M | $91.44M | $98.55M | $114.79M |
| Total assets | $95.58M | $98.06M | $54.47M | $62.26M | $67.66M | $51.00M | $57.98M | $68.11M | $79.01M | $92.43M | $99.36M | $115.62M |
| Current liabilities | $3.28M | $3.57M | $4.14M | $4.22M | $4.52M | $5.04M | $3.91M | $6.24M | $8.19M | $12.16M | $10.09M | $9.26M |
| Total liabilities | $3.28M | $3.57M | $4.20M | $4.30M | $4.63M | $5.04M | $3.91M | $6.45M | $8.19M | $12.41M | $10.20M | $9.44M |
| Shareholders' equity | $92.30M | $94.50M | $50.28M | $57.96M | $63.03M | $45.96M | $54.07M | $61.65M | $70.82M | $80.02M | $89.16M | $106.18M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.28M | $45.92M | -$7.98M | -$4.68M | -$6.55M | -$8.38M | -$10.21M | -$9.86M | -$13.54M | -$10.42M | -$15.46M | -$11.64M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | - | $12.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | - | -$11.66M |
| Investing cash flow | $0 | $5.50M | $17.90M | $3.92M | $29.23M | $3.04M | $11.08M | -$1.57M | $22.20M | $2.60M | $10.26M | $16.91M |
| Financing cash flow | $120.0K | $131.0K | $3.0K | $6.0K | $0 | $10.0K | $0 | $18.0K | -$11.0K | $5.19M | $0 | $72.0K |
| Stock-based compensation | $405.0K | $424.0K | $613.0K | $774.0K | $1.05M | $1.61M | $1.88M | $1.96M | $2.03M | $1.92M | $2.09M | $2.55M |
| Depreciation and amortization | $0 | $2.0K | $3.0K | $3.0K | $35.0K | $26.0K | $28.0K | $30.0K | $32.0K | $34.0K | $35.0K | $36.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -100.0% | 0.0% | 484.2% | -29.1% | -29.1% | - | - | - | - | - | - |
| Operating margin | - | - | -4119.3% | -2888.3% | -3266.5% | -4743.9% | -4561.3% | -30547.4% | -4035.5% | -5697.3% | - | - |
| Net margin | - | - | -3904.7% | -2636.0% | 7554.7% | -4576.9% | -4452.4% | -29063.2% | -3834.8% | -5430.1% | - | - |
| Current ratio | 28.87 | 27.26 | 12.92 | 14.50 | 14.74 | 9.98 | 14.68 | 10.87 | 9.55 | 7.52 | 9.77 | 12.39 |
Source: XBRL data Rallybio Corporation files with the SEC, latest filing dated Oct 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-8, first reported Mar 16, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
RLYB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RLYB | - | - | $26.81M | - | $84.3M |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| REGN | $16.90B | +18.6% | $4.82B | 28.5% | $95.17B |
RLYB FAQ
6 questionsIs RLYB profitable?
Yes. Rallybio Corporation earned $26.81M in net income for the twelve months ended Sep 30, 2026.How much cash and debt does RLYB have?
Rallybio Corporation reported $90.69M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is RLYB revenue growing?
Rallybio Corporation's revenue changed +34.9% in fiscal 2025, to $858.0K.What is RLYB earnings per share?
Diluted earnings per share were $4.61 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did RLYB last report financial results?
The latest statements here come from Rallybio Corporation's 10-Q filed on Oct 27, 2026, covering the period ended Sep 30, 2026.Where does this RLYB financial data come from?
Quantisnow builds these statements from the structured XBRL data Rallybio Corporation files with the SEC. It is provided for information only and is not investment advice.